Intellia (NTLA) Q2 Revenue Jumps 106%
Intellia Therapeutics (NASDAQ:NTLA), a biotechnology company developing CRISPR-based gene-editing therapies, reported second quarter 2025 results on August 7, 2025. The headline news was a significant increase in collaboration revenue to $14.2 million (GAAP) for Q2 2025, which beat the analyst estimate of $11.9 million (GAAP). Net loss per share (GAAP) narrowed to $(0.98) for Q2 2025, an improvement from $(1.52) in Q2 2024. Both research and administrative spending declined, helping extend the company's cash runway into the first half of 2027. The quarter saw critical clinical milestones for lead programs, with trial recruitment moving faster than previously planned and strong clinical outcomes reported. Overall, the period marked better-than-expected progress both financially and operationally.
Source: Analyst estimates for the quarter provided by FactSet.
Intellia Therapeutics is focused on developing CRISPR gene-editing therapies for severe genetic diseases. Its main programs are in hereditary angioedema (HAE) and transthyretin amyloidosis (ATTR), both rare disorders with limited treatment options.
Source Fool.com
Intellia Therapeutics Inc Stock
The stock is one of the favorites of our community with 23 Buy predictions and 3 Sell predictions.
Based on the current price of 9.8 € the target price of 47 € shows a potential of 379.49% for Intellia Therapeutics Inc which would more than double the current price.
